Antithrombin concentrate (ATIIIC)

ApprovedBiologic

Sanofi

Antithrombin concentrate (ATIIIC) is one of 62 biologic programs targeting Hemophilia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

Hemophilia aActive, not recruiting

HemophiliaApproved

Active, not recruiting

Hemophilia aPhase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

16 2

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

2 3

Eptacog Alfa

Novo Nordisk

Phase 3

1 4

Antithrombin concentrate (ATIIIC)

Sanofi

Approved

3 5

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

1 6

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Phase 3

3 7

Recombinant Factor VIII

Bayer

Phase 3

2 8

Translarna

PPTC Therapeutics

Phase 2

1 9

PF-06741086

Pfizer

Phase 3

1 10

Marstacimab

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Active, not recruiting

Hemophilia

NCT05662319

Q4 2029

Post-ApprovalRecruiting

Hemophilia

NCT06145373

Q4 2031

Phase 3Recruiting

Hemophilia

NCT07285460

Clinical

Trials by Indication[1]

Hemophilia3 trials

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Recruiting· Sanofi logo

Sanofi·Phase 4·NCT06145373·20 enrolled

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT05662319·91 enrolled

An Open-label, Parallel, Phase 3, Two-arm Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B With or Without Inhibitory Antibodies to Factors VIII or IX

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07285460·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Antithrombin concentrate (ATIIIC). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antithrombin concentrate (ATIIIC) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antithrombin concentrate (ATIIIC). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Sanofi

Antithrombin concentrate (ATIIIC)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2029

Q4 2031

Trials by Indication[1]

Hemophilia3 trials

References

Drug Info

Quick Facts

Related News